Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction

This publication has 43 references indexed in Scilit:

• Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis
  Blood, 2006
• Development of Thalassaemic Iron Overload Cardiomyopathy despite Low Liver Iron Levels and Meticulous Compliance to Desferrioxamine
  Acta Haematologica, 2006
• Low Serum Ferritin Levels are Misleading for Detecting Cardiac Iron Overload and Increase the Risk of Cardiomyopathy in Thalassemia Patients. The Importance of Cardiac Iron Overload Monitoring Using Magnetic Resonance Imaging T2 and T2*
  Hemoglobin, 2006
• Reversal of heart failure in thalassemia major by combined chelation therapy: a case report
  European Journal of Haematology, 2004
• Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major
  Blood, 2004
• Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death
  New England Journal of Medicine, 2004
• Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia
  Journal of Magnetic Resonance Imaging, 2003
• Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register
  The Lancet, 2000
• Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major
  New England Journal of Medicine, 1994
• Current Treatment of Cooley's Anemia
  Annals of the New York Academy of Sciences, 1990